Abstract
One of the most important causes of anticancer treatment failure is the development of multidrug resistance (MDR). The main characteristics of tumor cells displaying the MDR phenomena are cross‐resistance to structurally unrelated cytotoxic drugs having different mechanisms of action and the overexpression of the MDR1 gene, which encodes a transmembrane glycoprotein named P‐ glycoprotein (P‐gp). This study evaluated whether bromocriptine, a D2 dopaminergic receptor agonist, influenced anticancer drug cytotoxicity and P‐gp activity in a P‐gp‐expressing cell line compared to a non‐expressing subline. The Ki values for P‐gp of cyclosporine and verapamil were 1.09 and 540 μM, respectively, and that of bromocriptine was 6.52 μM in a calcein‐AM efflux assay using porcine kidney epithelial LLC‐PK1 and L‐MDR1 cells, overexpressing human P‐gp. Bromocriptine at 10 μM reduced the IC50 of doxorubicin (DXR) in K562‐DXR from 9000 to 270 ng/ml and that of vincristine (VCR) in K562‐VCR from 700 to 0.30 ng/ml, whereas the IC50 values of DXR and VCR in the K562 subline were only marginally affected by these drugs. Bromocriptine restored the anticancer effect of DXR, VCR, vinblastine, vinorelbine and etoposide on MDR‐tumor cells overexpressing P‐gp. These observations suggest that bromocriptine has the potential to reverse tumor MDR involving the efflux protein P‐gp in the clinical situation.
Keywords: P‐Glycoprotein, Bromocriptine, Multidrug resistance
Full Text
The Full Text of this article is available as a PDF (143.4 KB).
REFERENCES
- 1.Juliano , R. L. and Ling , L.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants . Biochim. Biophys. Acta , 455 , 152 – 162 ( 1976. ). [DOI] [PubMed] [Google Scholar]
- 2.Fojo , A. , Lebo , R. , Shimizu , N. , Chin , J. E. , Roninson , I. B. , Merlino , G. T. , Gottesman , M. M. and Pastan , I.Localization of multidrug resistance‐associated DNA sequences to human chromosome 7 . Somat. Cell Mol. Genet. , 12 , 415 – 420 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 3.Chen , C. J. , Chin , J. E. , Ueda , K. , Clark , D. P. , Pastan , L , Gottesman , M. M. and Roninson , I. B.Internal duplication and homology with bacterial transport proteins in the mdrl (P‐glycoprotein) gene from multidrug‐resistant human cells . Cell , 47 , 381 – 389 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 4.Gottesman , M. M. and Pastan , I.The multidrug‐transporter, a double‐edged sword . J. Biol. Chem. , 263 , 12163 – 12166 ( 1988. ). [PubMed] [Google Scholar]
- 5.Gros , P. , Croop , J. and Housman , D.Mammalian multi‐ drug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins . Cell , 47 , 371 – 380 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 6.Hyde , S. C. , Emsiely , P. , Hartshorn , M. J. , Mimmack , M. M. , Gileadi , U. , Pearce , S. R. , Gallagher , M. P. , Gill , D. R. , Hubbard , R. E. and Higgins , C. F.Structure model of ATP‐ binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport . Nature , 346 , 362 – 365 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 7.Ambudkar , S. V. , Dey , S. , Hrycyna , C. A. , Ramachandra , M. , Pastan , I. and Gottesman , M. M.Biochemical, cellular, and pharmacological aspects of the multidrug transporter . Amu. Rev. Pharmacol. Toxicol. , 39 , 361 – 398 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 8.Goldstein , L. J.Clinical reversal of drug resistance . Curr. Probl. Cancer , 19 , 65 – 124 ( 1995. ). [PubMed] [Google Scholar]
- 9.Orlowski , S. , Valente , D. , Garrigos , M. and Ezan , E.Bromocriptine modulates P‐glycoprotein function . Biochem. Biophys. Res. Commun. , 244 , 481 – 488 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 10.Thorner , M. O. , Fluckiger , E. and Calne , D. B. “ Bromocriptine. A Clinical and Pharmacological Review ” ( 1980. ). Raven Press; , New York . [Google Scholar]
- 11.Shiraki , N. , Hamada , A. , Yasuda , K. , Fujii , J. , Arimori , K. and Nakano , M.Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P‐glycoprotein . Biol. Pharm. Bull. , 23 , 1528 – 1531 ( 2000. ). [DOI] [PubMed] [Google Scholar]
- 12.Shiraki , N. , Hamada , A. , Ohmura , T. , Tokunaga , J. , Oyama , N. and Nakano , M.Increase in doxorubicin cytotoxicity by inhibition of P‐glycoprotein activity with lomerizine . Biol. Pharm. Bull , 24 , 555 – 557 ( 2001. ). [DOI] [PubMed] [Google Scholar]
- 13.Shibata , H. , Kanamaru , R. , Sato , T. , Ishioka , C. , Konishi , Y. , Ishikawa , A. , Wakui , A. and Tsuruo , T.Increase in the level of P‐glycoprotein mRNA expression in multidrug‐ resistant K562 cell lines treated with sodium butyrate is not accompanied with erythroid differentiation . Jpn. J. Cancer Res. , 81 , 1214 – 1217 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Liminga , G. , Nygren , P. and Larsson , R.Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P‐glycoprotein‐mediated resistance: effect of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833 . Exp. Cell Res. , 212 , 291 – 296 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 15.Feller , N. , Kuiper , C. M. , Lankelma , J. , Ruhdal , J. K. , Scheper , R. J. , Pinedo , H. M. and Broxterman , H. J.Functional detection of MDR1/P170 and MRP/P190‐mediated multidrug resistance in tumour cells by flow cytometry . Br. J. Cancer , 72 , 543 – 549 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Srinivas , R. V. , Middlemas , D. , Flynn , P. and Fridland , A.Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters . Antimicrob. Agents Chemother. , 42 , 3157 – 3162 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lan , L. B. , Ayesh , S. , Lyubimov , E. , Pashinsky , I. and Stein , W. D.Kinetic parameters for reversal of the multi‐drug pump as measured for drug accumulation and cell killing . Cancer Chemother. Pharmacol. , 38 , 181 – 190 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 18.Back , S. A. , Khan , R. , Gan , X. , Rosenberg , P. A. and Volpe , J. J.A new Alamar Blue viability assay to rapidly quantify oligodendrocyte death . J. Neurosci. Methods , 91 , 47 – 54 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 19.Grandjean , F. , Bremaud , L. , Verdier , M. , Robert , J. and Ratinaud , M. H.Sequential gene expression of P‐glycoprotein (P‐gp), multidrug resistance‐associated protein (MRP) and lung resistance protein: functional activity of P‐gp and MRP present in the doxorubicin‐resistant human K562 cell lines . Anticancer Drugs , 12 , 247 – 258 ( 2001. ). [DOI] [PubMed] [Google Scholar]
- 20.Shiraki , N. , Hamada , A. , Tokunaga , J. , Nakano , M. and Kawaguchi , T.Circumvention of P‐glycoprotein‐mediated multidrug resistance of tumor cells with ergot alkaloids derivatives . Jpn. J. Cancer Res. , 91 ( Suppl. ), 191 ( 2000. ). [Google Scholar]
- 21.Drewe , J. , Mazer , N. , Abisch , E. , Krummen , K. and Keck , M.Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation . Eur. J. Clin. Pharmacol. , 35 , 535 – 541 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 22.Schran , H. F. , Bhuta , S. I. , Schwarz , H. J. and Thorner , M. O.The pharmacokinetics of bromocriptine in man . Adv. Biochem. Psychophannacol. , 23 , 125 – 139 ( 1980. ). [PubMed] [Google Scholar]
- 23.Meier , J.Pharmacokinetics of the prolactin inhibitor bromocriptine . In “ Antihormone, Bedeutung in der Urologie ,” Klinische und Experimental Urologie; , Bd. 3 , pp. 204 – 212 ( 1981. ). Zuckschwerdt Verlag; , München . [Google Scholar]